Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease.
Lebon D, Dujardin A, Caulier A, Joris M, Charbonnier A, Gruson B, Quint M, Castelain S, François C, Lacassagne MN, Guillaume N, Marolleau JP, Morel P.
Lebon D, et al. Among authors: guillaume n.
Leuk Res. 2023 Feb;125:107005. doi: 10.1016/j.leukres.2022.107005. Epub 2022 Dec 24.
Leuk Res. 2023.
PMID: 36580876